HIV transmission and 24-month survival in a randomized trial of HAART to prevent MTCT during pregnancy and breastfeeding in Botswana
- 31 July 2013
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 27 (12) , 1911-1920
Abstract
Objectives: HAART for prevention of mother-to-child HIV transmission (MTCT) may impact long-term survival of women and children. Design: Randomized clinical trial. Methods: HIV-infected pregnant women with CD4+ cell count at least 200 cells/μl were randomly assigned to abacavir, zidovudine, lamivudine (arm A) or lopinavir–ritonavir, zidovudine–lamivudine (arm B) from week 26 to 34 gestation through planned weaning by 6 months postpartum. Women with baseline CD4+ cell count less than 200 cells/μl received nevirapine–zidovudine–lamivudine indefinitely (Obs arm), as did randomized women later qualifying for treatment. Results: Among 560 randomized and 170 observational women enrolled, there were 14 deaths (1.9%) – one antenatally (Obs), three from delivery to 6 months postpartum (1 arm A, 2 Obs), and 10 from 6 to 24 months postpartum (5 arm A, 3 arm B, 2 Obs). Time to death or CD4+ cell count below 200 cells/μl was shorter in arm A vs. B (P = 0.03). Of the 709 live-born children, 97% breastfed for a median of 5.8 months. Of 37 (5.2%) deaths by 24 months, nine were before breastfeeding initiated (3 arm A, 2 arm B, 4 Obs); six while breastfeeding (1 arm A, 2 arm B, 3 Obs); and 22 after weaning (9 arm A, 11 arm B, 2 Obs). Only eight children (1.1%) were HIV-infected at 24 months (6 arm A, 1 arm B, 1 Obs), all before 6 months. Conclusion: Low MTCT was maintained through extended follow-up in all arms. Disease progression appeared slower after discontinuing protease inhibitor-based HAART, but a concerning number of maternal deaths occurred after stopping either regimen. Strategies to improve maternal and child survival in the postintervention period are required.Keywords
This publication has 22 references indexed in Scilit:
- Protecting infants of HIV-positive mothers in MalawiThe Lancet, 2012
- Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trialThe Lancet, 2012
- Unresolved Antiretroviral Treatment Management Issues in HIV-Infected ChildrenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Birth weight for gestational age norms for a large cohort of infants born to HIV-negative women in Botswana compared with norms for U.S.-born black infantsBMC Pediatrics, 2011
- Postexposure Prophylaxis of Breastfeeding HIV-Exposed Infants With Antiretroviral Drugs to Age 14 Weeks: Updated Efficacy Results of the PEPI-Malawi TrialJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Early Weaning of HIV-Exposed Uninfected Infants and Risk of Serious Gastroenteritis: Findings from Two Perinatal HIV Prevention Trials in Kampala, UgandaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIVAIDS, 2007
- Breastfeeding Plus Infant Zidovudine Prophylaxis for 6 Months vs Formula Feeding Plus Infant Zidovudine for 1 Month to Reduce Mother-to-Child HIV Transmission in BotswanaJAMA, 2006
- How many child deaths can we prevent this year?The Lancet, 2003
- Rates of Disease Progression by Baseline CD4 Cell Count and Viral Load After Initiating Triple-Drug TherapyJAMA, 2001